- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00471055
Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 0.0125% of Capsaicin to Placebo (OAknee)
July 8, 2008 updated by: Khon Kaen University
The purpose of this study is to determine whether capsaicin gel is effective in treating mild to moderate degrees of osteoarthritis of the knee in the elderly patient compared with placebo gel.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Osteoarthritis (OA) is the most common form of arthritis in the population.
It is characterized pathologically by both focal loss of articular cartilage and marginal and central new bone formation.
OA of knee, the principal large joint to be affected, results in disabling knee symptoms in an estimated 10% of people older than 55 years, a quarter of whom are severely disabled.
The risk of disability attributable to knee OA alone is as great as that due to cardiac disease and greater than that due to any other medical disorder in the elderly.
A recent World Health Organization report on the global burden of disease indicates that knee OA is likely to become the fourth most important global cause of disability in women and the eighth most important in men.
Knee OA is associated with symptoms of pain and functional disability.
Physical disability arising from pain and loss of functional capacity reduces quality of life and increases the risk of further morbidity and mortality.
Current treatments aim at alleviating these symptoms of mild to moderate OA by several different methods: non-pharmacological treatment (for example education, exercise, lifestyle changes) or pharmacological treatments(for example paracetamol, NSAIDs and Capsaicin gel topical treatments).
Current evidence to support the various treatments in current use, however, is very variable.
Capsaicin, the active principle of hot chili pepper, is thought to selectively stimulate unmyelinated C fibre afferent neurons and cause the release of substance P. Prolonged application of capsaicin reversibly depletes stores of substance P, and possibly other neurotransmitters, from sensory nerve endings.
This reduces or abolishes the transmission of painful stimuli from the peripheral nerve fibres to the higher centres.There were many study on Capsaicin gel to confirm the effectiveness of capsaicin gel in many dosages.
However, there has been no efficacy study on the capsaicin 0.0125% of the Thai produce "Capsika gel " before, therefore, this study is proposed.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Khon Kaen
-
Khon kaen University, Khon Kaen, Thailand, 40002
- Weerachai Kosuwon
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects eligible for enrollment in the study must meet all of the following criteria:
- Subjects who are capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- Ambulatory nom pregnant females and males 40-<80 years of age.
- Subjects who withdraw pain medication or nutritional supplements for symptom relief for knee OA for a total of at least 15 days before screening visit 0.
- Pain at or below 80 mm on a 100 mm VAS in the index knee.
- A documented diagnosis of OA of the knee, or meeting American College of Rheumatology (ACR) clinical criteria for classification of idiopathic (primary) OA for at least 6 months prior to screening. If OA is presented in both knees the investigator will identify which knee will be X-rayed for study entry, with preference for the knee with more severe pain (<80mm VAS).
- Has documented radiographic evidence of OA of the knee from the screening Visit radiograph of grade 2 or 3 according to Kellgren and Lawrence Radiographic Grading.
- Subjects with baseline minimum joint space width in the medial compartment of the index knee of > 1.5 mm at Baseline, measured from radiographs using the MTP view.
- Subjects with baseline minimum joint space width in the lateral compartment of the index knee of > 2.5 mm at Baseline, measured from radiographs using the MTP view.
- Subject is able to understand and complete pain/function, global arthritis evaluation, and health outcome assessment.
Exclusion Criteria:
Subjects with any of the following criteria must not be enrolled in the study:
- Subjects with history of hypersensitivity to capsaicin.
- Subjects with skin lesion at the index knee.
- A history of lower extremity surgery within 6 months prior to screening V0.
- Significant prior injury to the index knee within 12 months prior to screening V0.
- Disease of the spine or other lower extremity joints of sufficient degree to affect the index knee.
Treatment with other drugs potentially affecting bone or cartilage metabolism as described below:
- chronic systematic corticosteroids
- hyaluronan injection into the index knee with in the previous 6 months.
- Diacerin treatment within the last 12 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
Capsaicin and placebo controlled,Cross-over design study
|
|
Placebo Comparator: B
Capsaicin and placebo controlled,Cross-over design study
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
VAS and WOMAC
Time Frame: 8 months
|
8 months
|
VAS and WOMAC
Time Frame: 8-month study
|
8-month study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: weerachai Kosuwon, M.D, Department of Orthopedics, Faculty of Medicine, Khon kaen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2007
Primary Completion (Actual)
October 1, 2007
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
May 8, 2007
First Submitted That Met QC Criteria
May 8, 2007
First Posted (Estimate)
May 9, 2007
Study Record Updates
Last Update Posted (Estimate)
July 9, 2008
Last Update Submitted That Met QC Criteria
July 8, 2008
Last Verified
April 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Khonkaen-ortho 1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee Joint
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
Stempeutics Research Pvt LtdStempeutics Research Malaysia SDN BHDCompleted
-
Government Medical College, BhavnagarCompletedOsteoarthritis of Knee JointIndia
-
University Hospital, GhentCompletedOsteoarthritis of the Knee JointBelgium
-
Chang Gung Memorial HospitalUnknownKnee Osteoarthritis | Arthropathy of Knee JointTaiwan
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Medical University of WarsawRecruitingKnee Osteoarthritis | Knee Arthritis | Joint; Arthrosis, PrimaryPoland
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
University of British ColumbiaSimon Fraser University; Vancouver General Hospital; Arthritis Research Centre...CompletedJoint Diseases | Knee OsteoarthritisCanada
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States